# Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

> **NCT03300843** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Melanoma
- Gastrointestinal Cancer
- Breast Cancer
- Ovarian Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** Peptide loaded dendritic cell vaccine

## Key facts

- **NCT ID:** NCT03300843
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-11
- **Primary completion:** 2019-07-09
- **Final completion:** 2019-09-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300843, "Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03300843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*